MediWound Ltd. (MDWD) MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Sector: Medicinal Chemicals & Botanical Products
Industry: Biotechnology
MediWound Ltd. NASDAQ:MDWD Healthcare · Biotechnology
Mkt Cap $172.89M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
MediWound to Report Third Quarter 2026 Financial Results
MediWound announced it will release third quarter 2026 financial results on Thursday, November 12, 2026.
Management will host a conference call and webcast at 8:30 a.m. Eastern Time the same day to discuss results and provide a corporate update.
This is a scheduling notice only; no financial figures are disclosed ahead of the release.
• 3d ago AI analysis › Press Release ⚠ 2
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
MediWound received an additional $3.3 million in non-dilutive funding from the U.S. Department of War to advance a room-temperature-stable formulation of NexoBrid as a non-surgical debridement solution for battlefield burn care.
The award raises the total program budget to $21.8 million and supports development through an IND submission to the FDA, with work focused on completing CMC, establishing in-house cGMP manufacturing, and producing clinical batches.
The program falls within MediWound's existing North American license agreement with Vericel, which holds exclusive commercial and development rights to NexoBrid in the region.
• 1mo ago AI analysis › Press Release ⚠ 3
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
MediWound's independent Data and Safety Monitoring Board completed its pre-specified periodic safety review of the Phase III VALUE trial of EscharEx in venous leg ulcers and identified no safety concerns, recommending the study continue without modification.
The company reiterated that the pre-specified interim sample-size reassessment and completion of enrollment — 216 patients across roughly 40 sites in the U.S., Europe, and Israel — remain on track for the end of the first quarter of 2027.
The clean DSMB review modestly de-risks EscharEx, MediWound's lead pipeline candidate, but covers safety only; efficacy results from the pivotal trial remain the material upcoming catalyst.
• 1mo ago AI analysis › Press Release
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MediWound's CEO Ofer Gonen will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026 at the Lotte New York Palace Hotel in New York City.
The fireside chat, moderated by H.C. Wainwright Managing Director and Senior Healthcare Analyst Swayampakula Ramakanth, is scheduled for Monday, September 14, 2026, at 2:00 p.m. ET, with a live webcast available on MediWound's investor relations page.
This is a routine investor-outreach event with no new disclosure; MediWound markets the FDA-approved burn-care biologic NexoBrid and is advancing late-stage chronic-wound debridement candidate EscharEx.
• 1mo ago AI analysis › Press Release ⚠ 2
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
MediWound reported Q2 revenue of $3.1 million, down from $5.7 million in the prior year, with a net loss of $7.4 million and a cash position of $36 million following $20 million in cash burn during the first half.
The company reaffirmed its full-year 2026 revenue guidance of $24–26 million, driven by expected contributions from a new Master Services Agreement with Vericel under its BARDA contract.
Operational updates included record quarterly revenue and hospital unit sales for NexoBrid, while the Phase III VALUE trial for EscharEx remains on track for interim assessment and enrollment completion by the end of Q1 2027.
• 2mo ago AI analysis › Press Release
MediWound to Report Second Quarter 2026 Financial Results
MediWound announced that it will release its financial results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026.
Management will host a conference call and live webcast at 8:30 a.m. Eastern Time on that day to discuss the results and provide a corporate update.
The company is a biotechnology firm focused on enzymatic therapeutics, with FDA-approved product NexoBrid and late-stage pipeline candidate EscharEx.
• 3mo ago AI analysis › Press Release ⚠ 4
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
MediWound reported Q1 2026 revenue of $1.5 million, a 63% decline year-over-year, driven by timing of BARDA revenues and postponed shipments due to regional conflict.
The company posted a net loss of $3.0 million ($0.23 per share) and an operating loss of $8.0 million, with R&D expenses rising to $5.2 million due to the EscharEx Phase III trial.
Despite the weak quarter, MediWound reaffirmed its full-year 2026 revenue guidance of $24-26 million, citing expected government-related revenue in H2 2026 and a new $197M BARDA contract awarded to partner Vericel.
Clinical progress for EscharEx remains gradual, with enrollment slower than anticipated, though Medline joined the development program as a new collaborator.
• 5mo ago AI analysis › Press Release
MediWound to Report First Quarter 2026 Financial Results
MediWound announced it will release financial results for the first quarter ended March 31, 2026 on Wednesday, May 27, 2026.
Management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.
The company specializes in enzymatic, non-surgical therapies for tissue repair, including the FDA-approved biologic NexoBrid.
• 5mo ago AI analysis › Press Release
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
globenewswire.com • 6mo ago 
